Bacterial coinfection in influenza: A grand rounds review

JAMA

Volumn 309, Issue 3, 2013, Pages 275-282

  Chertow, Daniel S ^a   Memoli, Matthew J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; MOXIFLOXACIN; OSELTAMIVIR; PNEUMOCOCCUS VACCINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

2009 H1N1 INFLUENZA; ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLOOD GAS ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONSERVATIVE TREATMENT; DISEASE COURSE; DRUG EFFICACY; GRAM POSITIVE INFECTION; HUMAN; INFLUENZA; LABORATORY TEST; LEUKOPENIA; LIVER INJURY; MIXED INFECTION; PATHOGENESIS; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; THROMBOCYTOPENIA; WHEEZING; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; COMMUNICABLE DISEASE; CRITICAL ILLNESS; DIAGNOSIS; FATALITY; INFLUENZA VIRUS A H1N1; INTENSIVE CARE; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COINFECTION; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; CRITICAL ILLNESS; FATAL OUTCOME; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MORBIDITY; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS;

MLCS; MLOWN;

EID: 84872384525     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.194139     Document Type: Article

References (73)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76(1):105-115.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-970.
3. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695.
4. Estenssoro E, Ríos FG, Apezteguía C, et al; Registry of the Argentinian Society of Intensive Care SATI. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med. 2010;182(1):41-48.
5. Farias JA, Fernández A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36(6):1015-1022.
6. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872-1879.
7. Martín-Loeches I, Sanchez-Corral A, Diaz E, et al; H1N1 SEMICYUC Working Group. Communityacquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2011;139(3):555-562.
8. Rice TW, Rubinson L, Uyeki TM, et al; NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487-1498.
9. Webb SA, Pettilä V, Seppelt I, et al; ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl JMed. 2009;361(20):1925-1934.
10. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009.MMWRMorb Mortal Wkly Rep. 2009;58(38):1071-1074.
11. Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med. 2010;134(2):235-243.
12. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med. 2010;181(1):72-79.
13. National Vital Statistics System. Deaths: Final Data for 1976 Through 2009. CDC website. http://www.cdc.gov/nchs/deaths.htm. Accessed August 9, 2012.
14. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057-1062.
15. Morens DM, Taubenberger JK, Fauci AS. The persistent legacy of the 1918 influenza virus.NEngl J Med. 2009;361(3):225-229.
16. Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16(5):e321-e331.
17. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
18. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One. 2009;4(12):e8540.
19. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197(9):1226-1234.
20. Randolph AG, Vaughn F, Sullivan R, et al; Pediatric Acute Lung Injury and Sepsis Investigator's Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450-e1458.
21. Reed C, Kallen AJ, Patton M, et al. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. Pediatr Infect Dis J. 2009;28(7):572-576.
22. Centers for Disease Control and Prevention (CDC). Severe coinfection with seasonal influenza A (H3N2) virus and Staphylococcus aureus - Maryland, February-March 2012. MMWR Morb Mortal Wkly Rep. 2012; 61(16):289-291.
23. Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007.MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.
24. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894-899.
25. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998;101(3):643-649.
26. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.
27. Harford CG, Smith MR, Wood WB Jr. Sulfonamide chemotherapy of combined infection with influenza virus and bacteria. J Exp Med. 1946;83:505-518.
28. Lewis PA, Shope RE. Swine influenza: II, a hemophilic bacillus from the respiratory tract of infected swine. J Exp Med. 1931;54(3):361-371.
29. Sanz-Ezquerro JJ, de la Luna S, Ortín J, Nieto A. Individual expression of influenza virus PA protein induces degradation of coexpressed proteins. J Virol. 1995;69(4):2420-2426.
30. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol. 1994;68(6):3667-3673.
31. Mori I, Komatsu T, Takeuchi K, Nakakuki K, Sudo M, Kimura Y. In vivo induction of apoptosis by influenza virus. J Gen Virol. 1995;76(Pt 11):2869-2873.
32. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis. 2003;187(6):1000-1009.
33. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis. 2004;190(3):519-526.
34. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis. 2005;192(2):249-257.
35. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe. 2007;2(4):240-249.
36. Tashiro M, Ciborowski P, Reinacher M, Pulverer G, Klenk HD, Rott R. Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. Virology. 1987;157(2):421-430.
37. Tashiro M, Ciborowski P, Klenk HD, Pulverer G, Rott R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature. 1987;325(6104):536-537.
38. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods. 2001;94(1-2):173-186.
39. Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol. 2010;42(4):450-460.
40. Okamoto S, Kawabata S, Nakagawa I, et al. Influenza A virus-infected hosts boost an invasive type of Streptococcus pyogenes infection in mice. J Virol. 2003;77(7):4104-4112.
41. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 1986;134(5):1040-1044.
42. Kash JC, Walters KA, Davis AS, et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio. 2011;2(5):e00172-e11.
43. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol. 2012;12(4):295-305.
44. Lee M-H, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis. 2010;201(4):508-515.
45. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized doubleblind placebo-controlled trial. JAMA. 1994;272(21):1661-1665.
46. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165-1174.
47. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the communitydwelling elderly. N Engl J Med. 2007;357(14):1373-1381.
48. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102- 1106.
49. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1-18.
50. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10(8):811-813.
51. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23(3):363-368.
52. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
53. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA. 2005;293(8):987-997.
54. Barry MA. A 29-year-old woman with flu-like symptoms: review of influenza diagnosis and treatment. JAMA. 2010;304(6):671-678.
55. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48(9):e89-e92.
56. Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;361(25):2493.
57. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72.
58. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14):1667-1672.
59. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53(3):277-279.
60. Cohen D. Search for evidence goes on. BMJ. 2012;344:e458.
61. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568-1575.
62. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65(6):510-515.
63. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-1944.
64. Siston AM, Rasmussen SA, Honein MA, et al; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517-1525.
65. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and metaanalysis of observational studies. Ann Intern Med. 2012;156(7):512-524.
66. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45(3):315-321.
67. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with communityacquired pneumonia. Arch Intern Med. 2004;164(6):637-644.
68. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080-2084.
69. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474.
70. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122(1):262-268.
71. Rello J, Rodríguez A, Ibañez P, et al; H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009;13(5):R148.
72. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009.MMWR Morb Mortal Wkly Rep. 2009;58(27):749-752.
73. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis. 2012;205(3):458-465.